Business
Travere Therapeutics Reports Third Quarter 2025 Financial Results
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nU.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter\n\n\nTotal revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million\n\n\nRetired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation\n\n\n2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI’s position as a foundational, nephroprotective therapy for IgAN\n\n\nCompany well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nTravere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update.\n\n\n“We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We continue to be pleased with the progress of our sNDA review in FSGS and are actively preparing for a potential FDA approval early next year. We are also making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase and have positioned the company to support long-term growth. We are entering the final months of 2025 in a position of strength as we remain focused on execution and on expanding our impact for people living with rare disease.”\n\n\nFinancial Results for the Quarter Ended September 30, 2025\n\n\nU.S. net product sales for the third quarter of 2025 were $113.2 million, compared to $61.0 million for the same period in 2024. The increase is attributable to growth in sales of FILSPARI. Total revenue for the third quarter of 2025 was $164.9 million, including recognition of a $40.0 million market access milestone from CSL Vifor and $9.3 million of non-cash license revenue associated with the Company’s partnership with Renalys. The $40.0 million market access milestone payment was received in October 2025.\n\n\nResearch and development (R&D) expenses for the third quarter of 2025 were $51.9 million, compared to $51.7 mi...